Over the last years, we have seen great progress in understanding the biological mechanisms underlying Alzheimer’s disease.1,2 Amyloid (Aβ) and tau levels from blood and CSF biomarkers are increasingly used to evaluate target engagement of anti-Aβ and anti-tau drugs. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.